Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

RRAGC Mutations Activate mTORC1 Signaling in Follicular Lymphoma

DOI: 10.1158/2159-8290.CD-RW2016-007 Published February 2016
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major finding: RRAGC mutations in follicular lymphoma activate mTORC1, even during amino acid depletion.

  • Approach: Exome sequencing together with in vitro experiments highlight the role of RRAGC mutants.

  • Impact: RRAGC mutations may be exploitable as therapeutic targets in patients with follicular lymphoma.

Follicular lymphoma is a B-cell neoplasm with characteristic mutations in epigenetic regulators and the t(14;18) translocation. Genome-wide genetic profiling provides the opportunity to discover novel biomarkers. To address this, Okosun, Wolfson, and colleagues performed exome sequencing on successive tumor biopsies from five patients with follicular lymphoma. In the discovery cohort, 4 of 5 patients had somatic mutations in RAS-related GTP binding C (RRAGC) which were observed in the dominant clone and maintained during disease progression. Targeted sequencing of a larger cohort of patients with follicular lymphoma found RRAGC mutations in 17% of patients, which were primarily missense mutations in highly conserved residues in the nucleotide-binding domain. RRAGC mutations were rare in other hematologic malignancies and nonhematologic cancers, suggesting a functional importance of this mutation in follicular lymphoma. RRAGC encodes RagC, which forms heterodimers with other RAG proteins and complexes with the vacuolar ATPase (V-ATPase) to activate mTOR complex 1 (mTORC1). The genes encoding two subunits of the V-ATPase complex, ATP6V1B2 and ATP6AP1, were also frequently and mutually exclusively mutated in follicular lymphoma, and strongly correlated with the presence of RRAGC mutations. RNA sequencing of RRAGC-mutant follicular lymphoma tumors showed upregulation of mTOR targets compared to wild-type. The binding of RAG GTPase heterodimers to mTORC1 is essential for its amino acid–induced activation, and mutant RagC exhibited increased binding to the mTORC1 subunit Raptor. Further, RagC mutants activated mTORC1, even under conditions of amino acid deprivation. Taken together, these findings indicate that mutations in RRAGC activate mTORC1 signaling independent of amino acid availability and suggest that RagC may be an effective therapeutic target in follicular lymphoma.

Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, et al. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nat Genet 2015 Dec 21 [Epub ahead of print].

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.

  • ©2016 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 6 (2)
February 2016
Volume 6, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
RRAGC Mutations Activate mTORC1 Signaling in Follicular Lymphoma
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
RRAGC Mutations Activate mTORC1 Signaling in Follicular Lymphoma
Cancer Discov February 1 2016 (6) (2) 117; DOI: 10.1158/2159-8290.CD-RW2016-007

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
RRAGC Mutations Activate mTORC1 Signaling in Follicular Lymphoma
Cancer Discov February 1 2016 (6) (2) 117; DOI: 10.1158/2159-8290.CD-RW2016-007
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
Show more Research Watch

Lymphoma

  • Metabolic Adaptation to Lymphoma Suppresses NK-Cell Antitumor Function
  • TBL1XR1 Mutations Bias toward Memory B-cell Fate to Promote Lymphoma
  • Mutant EZH2 Drives Follicular Lymphoma by Altering B-cell Dependencies
Show more Lymphoma
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement